home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0110.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
2KB
|
36 lines
Document 0110
DOCN M94A0110
TI Fluconazole versus ketoconazole in the treatment of oropharyngeal
candidiasis in HIV-infected children. Multicentre Study Group.
DT 9412
AU Hernandez-Sampelayo T; Department of Pediatric Infectious Diseases,
Hospital Infantil; Gregorio Maranon, Madrid, Spain.
SO Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):340-4. Unique Identifier
: AIDSLINE MED/94349966
AB In an open multicentre study the efficacy and safety of fluconazole
versus ketoconazole were evaluated in the treatment of 46 pediatric
patients with oropharyngeal candidiasis and AIDS or HIV infection.
Twenty-four subjects received oral fluconazole in a dosage of 3
mg/kg/day and 22 subjects received oral ketoconazole in a dosage of 7
mg/kg/day. The treatment duration ranged from 5 to 49 days. Results
showed that fluconazole and ketoconazole have comparable efficacy and
safety in the treatment of oropharyngeal candidiasis in HIV-infected
children. Patients treated with fluconazole had higher clinical and
mycological cure rates at the end of therapy (88% and 71% respectively)
than those treated with ketoconazole (81% and 57% respectively). One
case of drug-related side effects (diarrhea and abdominal pain) in a
patient receiving ketoconazole resulted in discontinuation of treatment.
Follow-up examinations 2 and 4 weeks post-treatment showed a comparably
high rate of relapse in both patient groups.
DE Adolescence Age Factors AIDS-Related Opportunistic Infections/*DRUG
THERAPY Candida/ISOLATION & PURIF Candidiasis, Oral/*DRUG
THERAPY/MICROBIOLOGY Child Child, Preschool Comparative Study Female
Fluconazole/*THERAPEUTIC USE Human Immunocompromised Host Infant
Infant, Newborn Ketoconazole/*THERAPEUTIC USE Male Pharyngeal
Diseases/*DRUG THERAPY Prospective Studies Time Factors CLINICAL
TRIAL JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).